絞り込み

16391

広告

Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.

著者 Kawano M , Morikawa K , Suda T , Ohno N , Matsushita S , Akatsuka T , Handa H , Matsui M
Virology.2014 Jan 5 ; 448C():159-167.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.

スターを付ける スターを付ける     (427view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Medical

Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-A(⁎)02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-A(⁎)02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. Because DNase I treatment of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
PMID: 24314646 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード